SCHEMBL6100606

SCHEMBL6100606

COc1cccc(Cn2cc(C3=CC(=O)NC3=O)c3cc(OCc4ccccc4)ccc32)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 4/20 0.46
PPARG P37231 3/20 0.46
PPARA Q07869 3/20 0.46
STK10 O94804 1/20 0.40
SLK Q9H2G2 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAOA P21397 3/20 0.38
MAOB P27338 3/20 0.38
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
IGF1R P08069 1/20 0.38
SRC P12931 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
EPHB4 P54760 1/20 0.38
CSNK2A1 P68400 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6098592 0.85 PPARD (0.48) PPARDPPARGPPARAMAOAMAOB
SCHEMBL6099720 0.82 PPARD (0.50) PPARDPPARGPPARAMAOAMAOB
SCHEMBL6100791 0.81 PPARD (0.44) PPARDPPARGPPARAMAOAMAOB
SCHEMBL6097466 0.79 MAOB (0.44) PPARDPPARGPPARAMEN1KMT2A
SCHEMBL6099511 0.78 MAOB (0.41) PPARDPPARGPPARAMEN1KMT2A
SCHEMBL7064807 0.77 MAPK1 (0.45) PPARDPPARGPPARAMAPT
SCHEMBL6799799 0.77 PPARG (0.41) PPARDPPARGPPARAMEN1KMT2A
SCHEMBL6099369 0.75 KDM4E (0.42) PPARDPPARGPPARAMAPTMAOA
SCHEMBL6098654 0.75 NPC1 (0.41) PPARDPPARGPPARAMAPTMAOA
SCHEMBL6098735 0.75 BAZ2B (0.48) PPARDPPARGPPARAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US disclosed
US-20040220202-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-11-04 US disclosed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US disclosed
EP-1283836-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS Aegera Therapeutics Inc. (CA) 2003-02-19 EP disclosed
WO-2001087887-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220202-A1 Neuroprotective and anti-proliferative compounds NLN, MKI67, BDNF PPARD 526/4885PPARG 575/4885PPARA 621/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF PPARD 437/4885PPARG 476/4885PPARA 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.